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Implications of Wound Healing on Subcutaneous
Photovoltaic Energy Harvesting
Maximilien Tholl , Marc Spring , Simone de Brot , Daniela Casoni, Adrian Zurbuchen ,
Hildegard Tanner , and Andreas Haeberlin
Abstract—Objective: Cardiac pacemakers must be
regularly replaced due to depleted batteries. A possible
alternative is proposed by subcutaneous photovoltaic
energy harvesting. The body’s reaction to an implant can
cause device encapsulation. Potential changes in spectral
light transmission of skin can influence the performance
of subcutaneous photovoltaic cells and has not yet been
studied in large animal studies. Methods: Subcutaneous
implants measuring changes in the light reaching the
implant were developed. Three pigs received those
implants and were analyzed for seven weeks. Spectral
measurements with known irradiation were performed to
identify possible changes in the transparency of the tissues
above the implant during the wound healing process. A
histological analysis at the end of the trial investigated
the skin tissue above the subcutaneous photovoltaic
implants. Results: The implants measured decreasing
light intensity and shifts in the light’s spectrum during
the initial wound healing phase. In a later stage of tissue
recovery, the implants measured a generally reduced light
intensity compared to the healthy tissue after implantation.
The spectral distribution of the measured light at the end
of the trial was similar to the first measurements. The
histological analysis showed subcutaneous granulation
tissue formation for all devices. Conclusion: The varying
reduction of light intensity reaching the implants means
that safety margins must be sufficiently high to ensure
the power. At the end of the wound healing process, the
spectral distribution of the light reaching the implant is
similar to healthy tissue. Significance: Optimizations of
spectral sensitivity of photovoltaic cells are possible.
Index Terms—Energy harvesting, in-vivo trial, medical
implant, subdermal photovoltaic cell, spectral light trans-
mission, wound healing.
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I. INTRODUCTION
THE use of active electronic implants such as cochlear [1],retinal [2] and cardiac implants increased in recent years.
Other examples of electronic diagnostic devices are implantable
cardiac loop recorders [3] or continuous glucose-monitoring
systems [4]. Electronic devices in general need to be supplied
by electric energy which is provided by an internal battery.
The cardiac pacemaker is the most common active electronic
implant [5]. It has an average power requirement of below
10 µW and an average lifetime of about 7 years [6]. However,
the median survival time of patients requiring permanent cardiac
pacing is 8.5 years [7]. This discrapency contributes to a high
replacement rate of 25 % for cardiac pacemakers [8].
Energy harvesting within the human body presents an alter-
native to primary batteries. There are multiple approaches to
harvest energy from e.g. body movement or blood flow, but
this study focuses on subcutaneous photovoltaic cells which use
light to recharge the implant. The idea of using subcutaneous
photovoltaic cells to recharge active electronic implants has
been previously studied and discussed. The light transmission
of human skin was extensively modelled using Monte Carlo
simulations [9]. A meteorological data evaluation estimated
the real life potential of subcutaneous photovoltaic harvest-
ing [10]. Further research on a medical photovoltaic power sup-
ply [11], an energy autonomous photovoltaic powered CMOS
sensor [12] and a photovoltaic harvester specialized on infrared
radiation [13] showed promising results. Moreover, an ex-vivo
trial irradiated a photovoltaic module below a flap of porcine
skin [14]. Acute in-vivo trials with implanted photovoltaic
modules in mice [15], [16] and pigs [17], [18] showed promising
power outputs. The trials showed that subcutaneous photovoltaic
modules at implantable size scales can generate between 2-10
mWcm−2 under midday solar irradiation. UV radiation is the
main cause of photovoltaic cell ageing [19]. The human skin
strongly absorbs UV radiation and therefore further increases the
photovoltaic cell’s durability, a competitive advantage compared
to other energy harvesting mechanisms, which often rely on
moving parts [20].
The aim of this study was to evaluate the influence of the
wound healing process after implantation on the light reaching
the implant and the spectral distribution of that light. Wound
healing leads to tissue remodelling, device encapsulation after
the implantation and will influence the power output. So far,
in vivo trials in literature are limited to short term experiments
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Fig. 1. The photovoltaic pacemaker measurement device as implanted
in the animals. The photovoltaic pacemaker (PPM) is on the left, the
measurement circuit (MC) part of the device is on the right. MCU =
Microcontroller unit, BT = Bluetooth.
which do not consider wound healing after implantation. This
long term in vivo trial during seven weeks provides new insights
on the influence of wound healing for subcutaneous photovoltaic
harvesting.
II. METHODS
The potential of subcutaneous photovoltaic energy harvesting
was tested in a long term in vivo trial. Subcutaneous photo-
voltaic pacemaker measurement devices were implanted into
pigs. Subsequently, we describe the custom-made device, that
was specifically built for this purpose and the experimental
protocol of the long-term animal trial.
A. Photovoltaic Pacemaker Measurement Device
The implant, that was used in this trial, is a measurement
device that enables to observe relevant changes within the skin
tissue above the included subcutaneous photovoltaic module. It
consists of two subsystems: a photovoltaic pacemaker (PPM)
with a battery that is charged by a photovoltaic module and
an independent measurement circuit (MC) with its own battery
that supervises the PPM. The photovoltaic pacemaker is a fully
functional cardiac pacemaker that constantly paces over a shunt
resistance and is recharged by the photovoltaic cell array. The
battery of the MC is charged by induction before the trial. The
MC measures the PPM’s current and voltage of the photovoltaic
module and its battery voltage. Furthermore, it measures time,
the open circuit voltage of a single photovoltaic cell, temper-
ature, its own battery voltage and the spectrum of the light
reaching the implant with 4 separate spectrometer ICs.
Fig. 1 shows the final prototype packaged in silicone (Elastosil
RT 601 A/B [21], Wacker Chemie AG, Stuttgart, Germany).
The photovoltaic module on the left, marked by the red box,
consists of a 4 by 4 array of monocrystalline silicon photovoltaic
cells (YKSM 4-4-0.5-5. [22], Yolk, Gyeonggi-do, Republic of
Korea). The measurement circuit on the right, marked by the blue
box, consists of many parts as e.g. the spectrometers, a single
photovoltaic cell, a bluetooth (BT) chip for communication and
a microcontroller unit (MCU) to handle all tasks. The single
photovoltaic cell on the measurement circuit is equivalent to
the cells on the photovoltaic module. It is unloaded and a good
low-light indicator.
Prior to the animal trial, the devices were extensively tested
on all functionalities as eg. performing measurements, commu-
nication via BT and many more. The photovoltaic cell array
was able to keep the PPM’s battery charged for indoor lighting
conditions. Furthermore, the prototype remained submerged in
water for six days and ethanol for one day.
1) Calibration of the Spectrometers on the Device:
There are four spectrometer integrated circuits (ICs) on the
device. Three (AMS AS7265x, 410 - 940 nm [23], ams Interna-
tional AG, Premstaetten, Austria) of them work together as one
spectrometer system covering 18 channels. The last spectrome-
ter (AMS AS7341, 410-670 nm [24], ams International AG,
Premstaetten, Austria) works independently and provides 11
channels. The device’s spectrometers were not calibrated. There-
fore, a reference spectrometer (Ocean Optics USB 4000 [25],
Ocean Optics Inc., Largo, Florida, USA) was used to measure the
spectral irradiation of a 400 W halogen light source to calibrate
the ICs in a spectral range of 500-850 nm. The prototype was
placed next to the reference spectrometer’s optical fiber. Both,
the device to be calibrated and the optical fiber of the reference
spectrometer, were placed in a box covered with a diffuser
because the device’s spectrometers are designed to be used for
diffuse light only. The halogen lamp was placed orthogonally
at one meter distance to the diffuser. The gain factors for each
channel and for every spectrometer chip was adjusted to fit the
reference spectrometer and to achieve maximum amplification
without sensor saturation.
B. Animal Trial
The experiment received an ethical approval from Canton
of Berne, Switzerland (Authorization number: BE87/19). The
animals included in the trial were three juvenile ‘Edelschwein’
pigs (2-3 months old), 2 male and one female, weighing 29, 30
and 36 kg at the beginning of the trial. The porcine skin model
was chosen because it is the most similar to humans in terms of
cellular composition, anatomy and physiology [26].
1) Implantation: All devices were subcutaneously im-
planted on the pigs’ flanks epifascially (as in conventional
pacemaker implantations in humans). The surgical procedure
was performed under general anaesthesia and consisted of a 6
cm long incision and tissue preparation and dissection until the
muscle’s fascia were reached. Subsequently, an epifascial pocket
was formed and the device was inserted into it. After insertion,
the pocket was closed by triple stitching. The implantations
were performed in the Experimental Anaesthesia, Department
of Veterinary Clinical Science, University Bern.
2) Reference Measurements: Reference measurements
were performed regularly to investigate the open circuit volt-
age as well as the subcutaneous, spectral irradiation. During
a reference measurement, a 400 W halogen lamp (Haloline
Eco Superstar 64 702, Osram GmbH, Munich, Germany) was
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positioned in a pre-calibrated 23 cm distance orthogonally above
the skin covering the implant to act as a solar simulator. The
measurements allow to observe changes in the spectral light
distribution under the skin during the wound healing process. A
reference measurement consists of a series of 30 fast, subsequent
measurements, which are averaged and used for analysis of the
above mentioned parameters.
All devices performed first reference measurements imme-
diately after implantation. The last measurements were all
performed with an identical device, which was placed in the
subcutaneous pockets of the devices after their explantation. In
contrary to the usual reference measurements, the first and last
measurements were repeated for 100 cm distance to cross-check
the measurement results and to reduce the influence of the correct
light source distance. The correct measurement distance is very
important as the light intensity in air decays proportionally to
1/distance2 [27].
3) First Week in the Veterinary Hospital: After implanta-
tion, the pigs were recovered from general anaesthesia under
veterinarian care in single recovery boxes and transferred to the
Swine and Ruminants Clinic of Department of Clinical Science,
University Bern where close veterinarian supervision of their
well-being was assured on a daily basis. Moreover, reference
measurements with the above mentioned halogen lamp in 23
cm distance were performed once per day for every device.
4) Six Weeks At the Farm: After this phase the animals
were transferred in group to a farm on the 6th or 7th post-
operative day (POD). The farm offered a large stable (20 m2)
with constant water access and the animals were fed twice a
day. They were kept in the stable for the first three days and then
were allowed to access the 60 m2 outside garden at any time.
The reference measurements with the halogen lamp in 23 cm
distance were repeated three times per week for the rest of the
trial.
5) Explantation: After six weeks at the farm, the animals
were transferred back to the Experimental Anaesthesia, De-
partment of Veterinary Clinical Science, University Bern, to
explant the devices under general anaesthesia. The first pig
underwent euthanasia at the end of the experimental day. The
two remaining pigs were recovered from general anaesthesia and
were permanently transferred to a sanctuary farm. A skin sample
over each device’s spectrometers was extracted for histological
analysis.
C. Histology
A histological analysis to identify relevant pathological
changes and to determine the thickness of each skin layer
(epidermis, dermis, subcutaneous tissue) and granulation tissue
layer above the implant was performed. For this purpose, full
thickness skin tissue samples of approximately 2 cm length and
5 mm width were extracted above the implant’s spectrometers.
They were then immediately fixed in 4% buffered formalin,
trimmed and routinely processed and stained with hematoxylin
and eosin for histological examination, which was performed by
a board certified veterinary pathologist. Histology slides were
Fig. 2. Device implantation procedure at the beginning of the trial. (a)
Preparation of the epifascial pocket for the device. (b) Insertion of the
device into the epifascial pocket. (c) Stitching of the pocket.
digitized for taking measurements of the tissue layers using the
software CaseViewer 2.4 (3DHistech Ltd.).
III. RESULTS
The following sections present the results that were acquired
during and after the animal trial.
A. Animal Trial
The following subsections present the findings that were
acquired during the animal trial.
1) Implantation: The implantation procedure was free from
complications. The procedure and results of the implantation
are illustrated in Fig. 2. No post-operative complications were
detected.
2) Overview of Measurements: The implanted devices
performed several measurements during the trial. Fig. 3 shows
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Fig. 3. Overview of exemplary measured parameters of one device.
The figure shows the postoperative phase during the first two weeks.
Data points of reference measurements under halogen lamp irradiation
are marked in red. The pacemaker battery’s voltage dropped on POD
2 which might indicate leakage currents and recovered on POD 7. The
peaks in VOC marked in red are due to an artificial light source used for
reference measurements, the remaining peaks are caused by sunlight.
an exemplary overview of measured variables such as the voltage
of the photovoltaic pacemaker battery VPM , the voltage of the
measurement circuit’s battery (VMC), the open circuit voltage
of the single photovoltaic cell on the MC (VOC) and the tem-
perature (Temp) under the MC (facing the pig). The animals
were transferred to the farm on POD 6 which lead to a visible
increase of VOC during daytimes. The VOC is a good indicator
for available light under low light conditions. The animals were
allowed to leave the stable and stay on an open, mostly shaded
field from POD 9 on, which led to a further significant increase
of VOC during daytime. The temperature stayed constant during
the trial and did not indicate inflammatory responses or device
malfunctions that led to heating of the device.
3) Power Output: The power output of the subdermal pho-
tovoltaic module dropped from 2.26 +/− 1.46 mW to 1.7 +/−
0.86 mW with the halogen lamp in 23 cm distance and an
active area of 2.56 cm2 when the first and last measurements
are compared. This corresponds to a power density of 0.88
mW/cm2 and 0.66 mW/cm2 at the beginning and the end of
the trial. The power of the halogen light source in 23 cm distance
is approximately 100mW/cm2. The subcutaneous photovoltaic
module was able to harvest 0.88 % of the irradiance’s power at
the beginning of the trial and 0.66 % at the end.
4) Open Circuit Voltage: The open circuit voltage VOC of
the single photovoltaic cell on the measurement circuit is an
indicator of the available light within the sensitive spectrum
(approximately 400 nm - 1000 nm) of the monocrystalline
silicon photovoltaic cell in low light conditions.
First vs. last measurement. The measurements in 23 cm and
100 cm distance show that the open circuit voltage of the single
photovoltaic cell decreased for all devices between the first and
the last measurement (see Fig. 4). The mean ± SD VOC across
all devices dropped from 0.51 ± 0.02 V to 0.44 ± 0.04 V in 23
cm distance (p= 0.016, Wilcoxon signed-rank test). For 100 cm
Fig. 4. Open circuit voltage (mean ± SD) of the single photovoltaic cell
on the MC during reference measurements in different distances on the
first and last day of the trial for all devices. (a) 23 cm distance. (b) 100
cm distance.
distance, the VOC dropped from 0.32 ± 0.02 V to 0.23 ± 0.03
V (p = 0.016, Wilcoxon signed-rank test). This corresponds to
a reduction of VOC by 14.1% and 28.9% between the first and
last measurement in 23 cm and 100 cm distance, respectively.
5) Spectral Light Measurements: The spectral distribu-
tion of light reaching the implant was measured during reference
measurements with the halogen light source. The spectrometers
are not calibrated for power measurements so only intensity
shifts within the spectra can be detected. Non-calibrated data is
plotted on grey background for all figures with spectral results.
First vs. last measurement. The absolute values of first spec-
trometer sensor (AS7265X) measured with the halogen lamp in
23 cm distance at the beginning and end of the animal trial
are shown in the top panel of Fig. 5. The spectrum of the
halogen lamp is plotted in black, illustrating the lamp’s spectral
radiation without skin coverage of the sensor. The mean spectral
intensities during the first (blue) and last (red) measurement for
all devices are presented in the top panel of Fig. 5. The mean
spectral intensities for all devices show an approximately even
reduction in intensity across all wavelengths. A comparison to
the known spectral irradiation of the halogen light source shows
that shorter wavelengths are increasingly absorbed by the skin
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Fig. 5. Absolute values (mean ± SD of all Devices) of both spectrom-
eter sensors during reference measurements with 23 cm distance on
the first and last day of the trial. The top and bottom panels show results
of the AMS AS7265X and the AMS AS7341 sensor, respectively. The
solid lines represent mean values of the reference measurements and
the shaded areas represent the respective standard deviations.
tissue. There is an absorption peak at a wavelength of 610 nm.
The bottom panel of Fig. 5 shows the absolute values of the
second sensor (AS7341) measured with the halogen lamp in
23 cm distance at the beginning and end of the animal trial.
The results of the second sensor support the findings of sensor
1 (AS7265X). On average, the intensities of all channels are
reduced in an advanced wound healing phase.
Development over time. The measured spectral light distribu-
tion during reference measurements for one device are shown
in Fig. 6. The black line shows the spectrum of the light source
measured without obstruction in front of the sensor at an arbi-
trary amplitude for visualization purposes. The coloured solid
lines show the mean values and the shaded areas the standard
deviations of the individual reference measurements.
6) Explantation: The explantation procedure for the animal
in the acute trial is shown in Fig. 7. The device visually did
not appear to be damaged at first glance during explantation. A
device encapsulation consisting of granulation tissue had formed
Fig. 6. Absolute values (mean ± SD) of the spectrometers during ref-
erence measurements for one device. The top and bottom panels show
results of the AMS AS7265X and the AMS AS7341 sensor, respectively.
The solid lines represent mean values of the reference measurements
and the shaded areas represent the respective standard deviations.
around the implant. The inner surface of the encapsulation was
smooth and did not grow into the device.
B. Histology
Fig. 8 shows two exemplary histological slides of the skin
above the implant collected at the time of explantation. A sum-
mary of the measured skin layer thicknesses is given in Table I.
A mean ± SD of the individual skin and granulation layers’
thickness and the overall thickness was calculated from three
measurements at different locations across the sample. Total
skin thickness above the implants varied significantly between
8.9 and 17.9 mm. Epidermis and dermis showed lower absolute
variations across the samples than other layers. Large thickness
variations were observed in the subcutaneous fatty layer between
4.3 mm and 10.1 mm and in the granulation tissue layer from
1.5 mm to 5.6 mm.
The skin tissues revealed a variably thick layer of granulation
tissue in the deep subcutaneous adipose tissue adjacent to the
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TABLE I
MEAN AND STANDARD DEVIATION IN mm OF THREE THICKNESS MEASUREMENTS AT DIFFERENT LOCATIONS OF THE HISTOLOGICAL SKIN SAMPLES ABOVE
THE INDICATED IMPLANTS
Fig. 7. Device 5 explantation procedure at the end of the trial.
implantation site in all assessable cases. Within the granulation
tissue, a mild to moderate, multifocal hemorrhage was common
and a mild to moderate, perivascular, predominantly lympho-
cytic and eosinophilic cellular inflammatory response was ob-
served in all cases. In addition, two cases were characterized
by the presence of foreign material (interpreted as silicone),
accompanied by a mild granulomatous inflammatory response.
The observed material is suspected to correspond to the devices
silicone rubber packaging. This material is known to persist in
tissues for a long time [28].
IV. DISCUSSION
The presented animal trial showed that the light intensity
reaching the implant is reduced during the wound healing pro-
cess due to a varying thickness of granulation tissue around the
implant. Furthermore, partial shading of a subdermal implant
can occur due to differences in granulation tissue thickness along
the implant.
A. Animal Trial
This section discusses the results that were acquired during the
animal trial. The power output of the PPM’s photovoltaic module
was not evaluated because all devices showed an accelerated
battery drain. The low voltage of the PPM’s battery meant that
the energy harvesting IC ‘BQ25570’ [29] (Texas Instruments
Incorporated, Dallas, Texas, USA) was not in its intended work
mode. As a consequence, power measurements are only partially
meaningful and cannot be interpreted reliably.
Fig. 8. Exemplary histological slides of the skin above the named
devices. The epidermis (1) is a thin layer on top of the slide, the dermis
(2) is a dense, vascularized tissue below the epidermis and the sub-
cutaneous tissue (3) consists mainly of adipocytes. Note the variably
thick layer of granulation tissue (4) in the deep subcutaneous tissue.
The tissue slides were stained with hematoxylin and eosin. (a) Device 2.
(b) Device 5.
1) Open Circuit Voltage: The open circuit voltage of the
single photovoltaic cell on the MC is a good indicator for
the available subcutaneous light because it is very sensitive
to changes in low light conditions. The maximum VOC of the
particular photovoltaic cell is 0.626 V which means that it was
never saturated during the measurements and therefore provides
reliable results. VOC decreased for all devices between the first
and last measurement.
2) Spectral Light Measurements: The spectral light in-
tensities were measured by the two spectrometers on the
MC to observe potential changes in the spectral distribution
of light reaching the implant in vivo. The measurements
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might allow to detect absorbers in certain spectral ranges
during the wound healing process. However, the measure-
ments do not allow to calculate spectral light transmission
curves.
The comparison between the first and the last measurements
showed that the light intensities decreased evenly for all wave-
lengths. The increased absorption of light for shorter wave-
lengths in the skin is in line with the results of our previously
conducted Monte Carlo simulations [9] and can be expected
because of the spectral absorption coefficient of the skin’s
constituents (melanosomes, blood, fat,...). An increased light
absorption at 610 nm was observed by sensor AS7265X (Fig. 5,
top panel) which is more pronounced at the beginning of the trial.
It cannot be explained by an increased absorption coefficient of
melanosome [30], blood [31], water [32] or fat [33]. Moreover,
a local coverage of the sensor is very unlikely because the
sensor IC is protected by the silicone rubber packaging and
very close to other channels which would have been affected as
well. Generally, the increased tissue thickness led to decreased
light under the skin. However, the spectral distribution of light
reaching the implant in the last measurement at an advanced
wound healing stage did not substantially differ from the first
measurement.
Observing the exemplary development of spectral measure-
ments of one device (see Fig. 6) shows that the spectral distri-
bution of the light reaching the implant is not evenly decreasing
during the initial wound healing phase, as might be expected
if only the first and last spectral measurements are compared.
Both spectrometers measured a large decrease in intensities
for wavelengths 500 - 600 nm during the first post-operative
day. The absorption coefficient of blood exhibits a local peak
in the same wavelength range [31]. The measured drop in
intensities could therefore be explained by internal bleeding
after implantation. Subsequently, the intensities of wavelengths
600-800 nm decrease faster than for the shorter wavelengths
(500-600 nm). This could be explained by the general tissue
growth and remodelling, vascularization and development of
granulation tissue around the implant [34] leading to a broad-
band absorption that increases over time. The drop in inten-
sities for shorter wavelengths could be decreased compared
to wavelengths > 600 nm because the tissue remodelling re-
moves the highly absorbing internal bleeding and therefore
counteracts the increasing general absorption. After 11 days, the
intensities increased again. This might indicate that the acute
wound healing with pronounced vascularization and possible
inflammation ended and the tissue remodelling reached a state
that is closer to the healthy tissue directly after implantation.
The last measurement shows decreased intensities across all
wavelengths except for λ > 800 nm. The decrease of intensities
can be explained by the significant growth of skin tissue above
the implants during the full trial. The higher the wavelengths,
the higher the penetration depth for light within the visible and
near IR spectrum. This could explain that the intensities for
λ > 800 nm did not decrease as much in the advanced wound
healing phase.
In summary, our spectral light measurements suggest that the
spectral distribution of light reaching the implant in an advanced
wound healing phase reached a state that is not different to
the spectral distribution of light under healthy tissue measured
directly after implantation. However, during the acute wound
healing phase in the first two weeks significant shifts in the
spectral distribution of light reaching the implant were observed.
B. Histology
Granulation tissue, which consists of well vascularized con-
nective tissue is known to form in response to skin implants [34].
The varying extent of granulation tissue in the examined skin
samples may indicate a difference in the implant placement
(implantation depth, relative positioning to ribs), mechanical
loads or the individual foreign body response of the pigs.
The explanted tissue samples were fixed in formaldehyd
without tension and therefore tend to bend and might appear
thicker than in its stretched, natural state. Although this is true
for all tissue samples, variations in e.g. sample length or width
might lead to an altered bending and consequently thickness
outcome. The true skin thicknesses in vivo might be thinner
than measured in the histological slices because the skin usually
is under tension.
Tissue fixation and processing may cause an artefactual vari-
ation in tissue layer thickness. Microscopic thickness measure-
ments may therefore be slightly imprecise and require inter-
pretation with certain caution. The large variation of the total
skin thickness reflect the differences in total body weight and
growth of the animals during the trial. Moreover, the variations of
thickness in subcutaneous fatty layer and granulation tissue layer
show that the design of a subcutaneous photovoltaic implant
needs to consider the worst case scenario and increase the safety
margins for sufficient power generation.
The total skin thickness measurements show a rather low
standard deviation within one sample. That means that the total
tissue thickness above one implant is approximately constant.
However, the fractions of the individual layers contributing to the
total thickness are not constant (see Table I). The transparency
across the layers varies and therefore the total skin thickness is
not sufficient for a power output prediction.
The thicknesses of individual layers showed the highest rel-
ative standard deviations in the epidermis and the granulation
tissue layer. The variation in thickness of the epidermis is
considered physiological and less relevant because of its overall
thinness. However, the larger standard deviation of the granu-
lation tissue layer is important for the development of a subcu-
taneous photovoltaic module. The granulation tissue is dense,
protein-rich and can be highly vascularized and therefore light
absorbing. If that is the case and the thickness of granulation tis-
sue varies significantly above the implant, partial ‘shading’ of the
photovoltaic cell array can occur. This can significantly reduce
the photovoltaic cell array’s efficiency [35]. An overview over
various different circuit and control techniques to optimize the
efficiency of a photovoltaic cell arrays under partial shading were
simulated and compared based on different requirements [36].
Further modelling of partially shaded photovoltaic cell arrays
showed that a ‘Total-Cross-Tied’ assembly of the photovoltaic
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cells performs best under partial shading conditions [37]. Gran-
ulation tissue is usually replaced by non-vascularized, collage-
nous scar tissue in the long-term [38] which should be less light
absorbing than dermal tissue [39].
C. Illumination and Possible Applications
The power output of the subcutaneous photovoltaic module
depends on the intensity and spectral distribution of the illumina-
tion. Solar radiation is one possible source for illumination that
varies in intensity during the day. Furthermore, artificial light
sources in buildings can contribute significantly to the harvested
energy [40]. Partial irradiation due to shadows and covering
of the skin above the implants by e.g. clothes can reduce the
subcutaneous photovoltaic module’s power output.
Subcutaneous photovoltaic harvesting could be envisioned as
a power source for a wide range of biomedical implants such as
glucose sensors or vital parameter monitors for example.
V. CONCLUSION
The results of the long-term porcine animal trial revealed
important findings for subcutaneous photovoltaic energy har-
vesting. Generally, the available light (and therefore the power)
below the skin will be reduced by different magnitudes depend-
ing on the total skin thickness and the level of granulation tissue
formation that is part of the normal wound healing process and
expected to occur as a reaction to skin implants. The granu-
lation tissue can lead to partial shading of the subcutaneous
photovoltaic array due to variations in thickness across one
implant. The spectral distribution of light below the skin changes
during the wound healing process but remains very similar
compared to healthy tissue. In future studies, optimizations of
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PHOTOVOLTAIC PACEMAKER MEASUREMENT DEVICE -
TECHNICAL DESCRIPTIONE
A. Photovoltaic Pacemaker Measurement Device
The implant, that was used in this trial, is a measurement
device that enables to observe relevant changes within the skin
Fig. 9. The photovoltaic pacemaker measurement device as implanted
in the animals. The measurement circuit part of the device is on the right,
the photovoltaic pacemaker is on the left.
tissue above the included subcutaneous photovoltaic module.
It consists of two main subsystems: a photovoltaic pacemaker
(PPM) with a battery that is charged by a photovoltaic module
and an independent measurement circuit (MC) with its own
battery that supervises the PPM. The photovoltaic pacemaker
is a fully functional cardiac pacemaker that constantly paces
over a shunt resistance and is recharged by the photovoltaic cell
array. The battery of the MC is charged by induction before
the trial. The MC measures the PPM’s current and voltage of
the photovoltaic module and its battery voltage. Furthermore, it
measures time, the open circuit voltage of a single photovoltaic
cell, temperature, its own battery voltage and the spectrum of
the light reaching the implant with 4 separate spectrometer ICs.
Fig. 9 shows the final prototype packaged in silicone rub-
ber (Elastosil RT 601 A/B [21], Wacker Chemie AG, 70 191
Stuttgart, Germany). The photovoltaic module on the left,
marked by the red box, consists of a 4 by 4 array of monocrys-
talline silicon photovoltaic cells (YKSM 4-4-0.5-5. [22], Yolk,
Gyeonggi-do, Republic of Korea). The cells are connected with
4 times 4 cells in series, which were then connected in parallel.
The measurement circuit on the right, marked by the blue
box, consists of many parts as e.g. the spectrometers, a single
photovoltaic cell, a bluetooth (BT) chip for communication and
a microcontroller unit (MCU) to handle all tasks. The single
photovoltaic cell on the measurement circuit is equivalent to the
cells on the photovoltaic module.
Prior to the animal trial, the devices were extensively tested
on all functionalities as eg. performing measurements, commu-
nication via BT and many more. The photovoltaic cell array
was able to keep the PPM’s battery charged for indoor lighting
conditions. Furthermore, the prototype submerged in water for
six days and ethanol for one day.
1) Calibration of the Spectrometers on the Device:
There are four spectrometer ICs on the device. Three (AMS
AS7265x, 410 - 940nm [23], ams International AG, 8141 Prem-
staetten, Austria) of them work together as one spectrometer sys-
tem covering 18 channels. The last spectrometer (AMS AS7341,
410-670 nm [24], ams International AG, 8141 Premstaetten,
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Austria) works independently and provides 11 channels. The
device’s spectrometers were not factory calibrated. Therefore,
a reference spectrometer (Ocean Optics USB 4000 [25], Ocean
Optics Inc., 33 777 Largo, Florida, USA) was used to measure
the spectral irradiation of a 400 W halogen light source. The
prototype was placed next to the reference spectrometer’s optical
fiber. Both, the device to be calibrated and the optical fiber of the
reference spectrometer, were placed in a box covered with a dif-
fuser because the device’s spectrometers are designed to be used
for diffuse light only. The halogen lamp was placed orthogonally
in one meter distance to the diffuser. The gain factors for each
channel and for every spectrometer chip was adjusted to fit the
reference spectrometer and to achieve maximum amplification
without sensor saturation. The signal amplitude of the halogen
light source on the reference spectrometer is low for λ < 500
nm and λ> 850nm. Therefore, a reliable calibration is possible
only for wavelengths 500 - 850 nm.
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